FDA approves Menveo, gives priority-review status to Gilenia

02/22/2010 | Wall Street Journal, The

Novartis received final approval from the FDA for meningococcal vaccine Menveo as well as priority-review designation for multiple sclerosis drug Gilenia. The approval for Menveo covers people ages 11 to 55, but Novartis said it also will seek approval for use of the vaccine in young children and infants.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC